title: High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.
abstract: Thirty-one consecutive patients with relapsed or refractory GCT received an HDT schedule including carboplatin, the dose of which was adjusted to measured glomerular filtration rate. There was one HDT-associated death (3%), due to acute renal failure. The 3-year probability of overall and disease-free survival for 21 patients with primary refractory disease or responsive relapse was 60% and 42%, respectively, while none of ten patients with refractory relapse have survived disease free.
authors.affiliation: Department of Haematology, Imperial College School of Medicine, Hammersmith Hospitals NHS Trust, London, UK.
authors.forename: M P
authors.initials: MP
authors.lastname: Lyttelton
authors.forename: E S
authors.initials: ES
authors.lastname: Newlands
authors.forename: C
authors.initials: C
authors.lastname: Giles
authors.forename: M
authors.initials: M
authors.lastname: Bower
authors.forename: A
authors.initials: A
authors.lastname: Guimaraes
authors.forename: S
authors.initials: S
authors.lastname: O'Reilly
authors.forename: G J
authors.initials: GJ
authors.lastname: Rustin
authors.forename: D
authors.initials: D
authors.lastname: Samson
authors.forename: E J
authors.initials: EJ
authors.lastname: Kanfer
mesh_terms: D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D018237:Germinoma / Q000188:drug therapy*; D005919:Glomerular Filtration Rate; D006801:Humans; D008297:Male; D011379:Prognosis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin